Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Pan-tumor × Oxaliplatin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 38 Colorectal Neoplasms 33 Rectal Neoplasms 23 Pancreatic Neoplasms 15 Colonic Neoplasms 11 Lymphoma, Large B-Cell, Diffuse 10 Cholangiocarcinoma 9 Neoplasm Metastasis 8 Adenocarcinoma 8 Neoplasms 7 Adenocarcinoma Of Esophagus 7 Carcinoma, Non-Small-Cell Lung 6 Carcinoma, Hepatocellular 6 Recurrence 5 Peritoneal Neoplasms 5 Locally Advanced Rectal Cancer 5 Gallbladder Neoplasms 5 Esophageal Neoplasms 5 Biliary Tract Neoplasms 5 Ovarian Neoplasms 4 Gastrointestinal Neoplasms 4 Advanced Solid Tumors 4 Carcinoma 3 Advanced Solid Tumor 3 Pathologic Complete Response 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Melanoma 2 Lymphoma 2 Esophageal Squamous Cell Carcinoma 2 Early Low Rectal Cancer 2

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡